Clinical Trial Update: Rituximab in Eosinophilic Granulomatosis With Polyangiitis [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting completion of a study evaluating rituximab for eosinophilic granulomatosis with polyangiitis (EGPA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Status: COMPLETED